Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Growth Metrics

AbCellera Biologics (ABCL) Change in Intangibles (2020)

AbCellera Biologics filings provide 1 years of Change in Intangibles readings, the most recent being $5.0 million for Q1 2020.

Quarterly Change in Intangibles changed N/A to $5.0 million in Q1 2020 from the year-ago period, while the trailing twelve-month figure was $5.0 million through Dec 2020, changed N/A year-over-year, with the annual reading at $560000.0 for FY2023, 72.0% down from the prior year.
Change in Intangibles hit $5.0 million in Q1 2020 for AbCellera Biologics.
Across five years, Change in Intangibles topped out at $5.0 million in Q1 2020 and bottomed at $5.0 million in Q1 2020.